VOSEVI 400-100-100 MG TABLET

SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR
$858.6880per EA

Strength

400; 100; 100 mg/1; mg/1; mg/1

NDC

61958240101

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

6/19/2024

Approval Type

New Drug (NDA)

FDA Application

NDA209195

On Market Since

7/18/2017

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Breast Cancer Resistance Protein Inhibitors
HCV NS3/4A Protease Inhibitors
Hepatitis C Virus NS3/4A Protease Inhibitor
Hepatitis C Virus NS5A Inhibitor
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
Organic Anion Transporting Polypeptide 2B1 Inhibitors
P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors
RNA Replicase Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

N/A

5Y

N/A

All

0.0%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.